MP07-66

• Description :

  MP07-66, a FTY720 analogue, is devoid of immunosuppressive effects and shows promising antitumor effects in chronic lymphocytic leukemia by disruption of the SET-PP2A complex leading to PP2A reactivation[1].

• CAS Number :

  [1938056-90-6]

• UNSPSC :

  12352005

• Hazard Statement :

  H315, H319, H335

• Target :

  Phosphatase

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/mp07-66.html

• Purity :

  99.86

• Solubility :

  DMSO : 250 mg/mL (ultrasonic)

• Smiles :

  CCCCCCOC1=CC=C(CNCC(OCC)OCC)C=C1

• Molecular Formula :

  C19H33NO3

• Molecular Weight :

  323.47

• Precautions :

  H315, H319, H335

• References & Citations :

  [1]Zonta F, et al. Lyn sustains oncogenic signaling in chronic lymphocytic leukemia by strengthening SET-mediated inhibition of PP2A. Blood. 2015;125 (24) :3747-3755.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported